Stocks and Investing
Stocks and Investing
Mon, November 7, 2016
[ 07:47 AM ] - United States, WOPRAI
[ 07:47 AM ] - United States, WOPRAI
[ 07:47 AM ] - United States, WOPRAI
[ 07:47 AM ] - United States, WOPRAI
[ 07:47 AM ] - United States, WOPRAI
[ 07:46 AM ] - United States, WOPRAI
[ 07:46 AM ] - United States, WOPRAI
[ 07:46 AM ] - United States, WOPRAI
[ 07:46 AM ] - United States, WOPRAI
[ 07:46 AM ] - United States, WOPRAI
[ 07:46 AM ] - United States, WOPRAI
[ 07:46 AM ] - United States, WOPRAI
[ 07:46 AM ] - United States, WOPRAI
[ 07:46 AM ] - United States, WOPRAI
[ 07:46 AM ] - United States, WOPRAI
[ 07:46 AM ] - United States, WOPRAI
[ 07:46 AM ] - United States, WOPRAI
[ 04:45 AM ] - United States, WOPRAI
[ 12:45 AM ] - United States, WOPRAI
[ 12:45 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Christopher Raymond Downgraded (BMRN) to Hold on, Nov 7th, 2016
Christopher Raymond of Piper Sandler, Downgraded "BioMarin Pharmaceutical Inc." (BMRN) to Hold on, Nov 7th, 2016.
Christopher has made no other calls on BMRN in the last 4 months.
There are 3 other peers that have a rating on BMRN. Out of the 3 peers that are also analyzing BMRN, 0 agree with Christopher's Rating of Hold.
These are the ratings of the 3 analyists that currently disagree with Christopher
- Andrew Peters of "Deutsche Bank" Initiated at Strong Buy on, Thursday, November 3rd, 2016
- Cory Kasimov of "JP Morgan" Maintained at Buy with Increased Target to $127 on, Friday, August 5th, 2016
- Gena Wang of "Barclays" Maintained at Buy with Increased Target to $125 on, Friday, August 5th, 2016
Contributing Sources